Since the combined sensitivity and specificity of actual biomarkers (e.g., C-reactive protein (CPR), Procalcitonin (PCT) and Interleukin-6 (IL-6)) do not allow for the rapid ascertainment of the diagnosis [14,15] and sepsis-related adverse outcomes rise with every hour of delay of proper intervention, new early biomarkers are urgently needed. The gene discussed is IL6; the disease is Sepsis.